JAK2 and Increased total eosinophil count: In the recent fifth edition of the World Health Organization classification, similar to the recent update to the International Consensus Classification, the category was renamed to “myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions” and both classifications added novel subtypes with new JAK2 rearrangements (e.g., BCR::JAK2, ETV6::JAK2) as well as fusions involving FLT3, and the ETV6::ABL1 fusion [2, 3].